# This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

> **NCT03207750** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1280 (actual)

## Conditions studied

- Rotavirus Infection
- Rotavirus Vaccines

## Interventions

- **BIOLOGICAL:** Rotarix
- **BIOLOGICAL:** Pediarix
- **BIOLOGICAL:** Hiberix
- **BIOLOGICAL:** Prevenar 13

## Key facts

- **NCT ID:** NCT03207750
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-14
- **Primary completion:** 2018-10-09
- **Final completion:** 2019-03-01
- **Target enrollment:** 1280 (ACTUAL)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207750, "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03207750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*